Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-24-034048
Filing Date
2024-11-08
Accepted
2024-11-08 08:01:12
Documents
55
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q mnpr20240930_10q.htm   iXBRL 10-Q 1036814
2 EXHIBIT 31.1 ex_718110.htm EX-31.1 13264
3 EXHIBIT 31.2 ex_718111.htm EX-31.2 13261
4 EXHIBIT 32.1 ex_718112.htm EX-32.1 8442
  Complete submission text file 0001437749-24-034048.txt   4825342

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA mnpr-20240930.xsd EX-101.SCH 39277
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE mnpr-20240930_cal.xml EX-101.CAL 19594
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mnpr-20240930_def.xml EX-101.DEF 302280
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE mnpr-20240930_lab.xml EX-101.LAB 255927
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mnpr-20240930_pre.xml EX-101.PRE 318451
58 EXTRACTED XBRL INSTANCE DOCUMENT mnpr20240930_10q_htm.xml XML 708992
Mailing Address 1000 SKOKIE BLVD SUITE 350 WILMETTE IL 60091
Business Address 1000 SKOKIE BLVD SUITE 350 WILMETTE IL 60091 8473880349
Monopar Therapeutics (Filer) CIK: 0001645469 (see all company filings)

EIN.: 320463781 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39070 | Film No.: 241438049
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)